TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06531798: Post-marketing Phase IV, Multicenter, Prospective Study to Observe the Safety and Tolerability of Breztri aerosphereTM Containing a Fixed Dose Combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol Fumarat

Sponsor: AstraZeneca · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 166 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$1,912,320

Rescue Site Savings

+$1,274,880

Unlock Full NCT06531798 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06531798 Rescue Dossier →